Backs FY25 revenue $1.275B-$1.355B, consensus $1.32B. Backs FY25 adjusted EBITDA $865M-$915M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme to acquire Elektrofi for upfront payment of $750M
- Halozyme price target raised to $90 from $75 at Benchmark
- Halozyme’s Strong Financial Performance and Strategic Positioning Justify Buy Rating Amid Patent Challenges
- Halozyme price target raised to $85 from $75 at H.C. Wainwright
- Halozyme price target raised to $80 from $75 at Morgan Stanley